Metabolic Enzymes Enjoying New Partnerships as RNA-Binding Proteins  by Castello, Alfredo et al.
Trends
Genetic control of metabolism is
currently best understood at the
level of transcription and epigenetics.
Only limited information is available
on post-transcriptional regulation of
metabolism.
While a few metabolic enzymes were
previously known to moonlight as
RNA-binding proteins in physiologically
relevant contexts, recent discoveries
highlight that several dozen of meta-
bolic enzymes belonging to a wide
spectrum of pathways exhibit RNA-
binding activity in living mammalianSpecial Issue: Systems Approach to Metabolic Disease
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In the past century, few areas of biology advanced as much as our understand-
ing of the pathways of intermediary metabolism. Initially considered unimpor-
tant in terms of gene regulation, crucial cellular fate changes, cell differentiation,
or malignant transformation are now known to involve ‘metabolic remodeling’
with profound changes in the expression of many metabolic enzyme genes. This
review focuses on the recent identiﬁcation of RNA-binding activity of numerous
metabolic enzymes. We discuss possible roles of this unexpected second
activity in feedback gene regulation (‘moonlighting’) and/or in the control of
enzymatic function. We also consider how metabolism-driven post-translational
modiﬁcations could regulate enzyme–RNA interactions. Thus, RNA emerges as
a new partner of metabolic enzymes with far-reaching possible consequences
to be unraveled in the future.cells.
Abundant RNA–enzyme interactions
might suggest novel roles of RNA in
affecting enzyme function, for instance,
as competitive inhibitors or allosteric
regulators. A function of RNA as
assembly scaffold for enzyme com-
plexes is also conceivable, with poten-
tially wide-ranging implications for our
understanding of how cells organize
and control metabolic ﬂux. Finally,
enzymes can moonlight as regulators
of (m)RNAs, as exempliﬁed by aconi-
tase/IRP1 and GAPDH.
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Metabolic enzymes were long considered to be constitutively expressed housekeeping proteins,
and even nowadays glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA continues
to be broadly used for normalization of real-time quantitative PCR experiments. However, this
traditional view is challenged by advances in many areas, including developmental, cancer, and
stem cell biology. The expression proﬁles of metabolic enzymes are controlled by cell identity,
which enables tissue metabolic specialization. Furthermore, metabolic enzyme expression is
also subject to ﬁne-tuning temporal regulation in response to feast/famine and to day/night
cycles (reviewed in [1,2], respectively).
The discovery of the nuclear hormone receptors (NHRs) in the 1980s represented a break-
through in the understanding of the transcriptional control of metabolic networks. NHRs
represent an extended family of ligand-responsive DNA-binding proteins that, upon activation,
can switch transcriptional programs in cooperation with coactivators or corepressors [3]. NHRs
are transcriptional master regulators of metabolism by altering the metabolic enzyme proﬁles in
response to feeding and fasting as well as circadian signaling. An illustrative example is the role of
NHRs in liver metabolism. Secretion of cortisol from the adrenal gland during prolonged
starvation induces the activation of the glucocorticoid receptor in the liver. This leads to the
transcription of two master regulators of sugar metabolism, glucose-6-phosphatase (G6PC)
and phosphoenolpyruvate carboxykinase (PECK), which promote the synthesis of glucose via
gluconeogenesis [1,4]. By contrast, liver X receptors (LXRs) and farnesoid X receptor (FXR) are
activated by feeding-induced synthesis of their respective ligands, oxysterols and bile acid. In
antagonism to fasting-activated NHRs, both LXRs and FXR suppress gluconeogenesis by746 Trends in Endocrinology & Metabolism, December 2015, Vol. 26, No. 12 http://dx.doi.org/10.1016/j.tem.2015.09.012
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(M.W. Hentze).upregulating the expression of glucokinase, which promotes glucose utilization, and by increas-
ing glycogen synthesis [5–7]. LXR activation also leads to an enhancement of triacylglycerol
synthesis by upregulating the genes involved in lipogenesis [8]. Thus, the study of transcription
factors such as NHRs and numerous others has contributed much to our understanding of the
genetic control of metabolism [1–3,9,10].
Importantly, transcriptomes only partially correlate with their corresponding proteomes, implying
that RNA-based post-transcriptional regulation should play an important role in sculpting cellular
proteomes [11]. Interestingly, a few metabolic enzymes had been noted to bind RNA themselves
and, in some instances, participate in the post-transcriptional control of speciﬁc mRNAs [12]. For
example, thymidine synthase (TYMS) can bind and inhibit the translation of its own RNA when
the levels of its substrates are low, establishing a negative feedback loop [13–15]. Conceptually,
such a mechanism represents a simple yet effective way to adjust to conditions when the
enzyme is not required. In this review, we discuss the emerging roles of protein–RNA interactions
in controlling metabolism.
Moonlighting Enzymes: Findings from RNA Interactomes
Over the past three decades, sporadic reports have shown that metabolic enzymes can
moonlight as RNA-binding proteins (RBPs) and, in some instances, regulate the expression
of their target mRNAs [12,16,17] (Table 1). These moonlighting enzymes (see Glossary)
participate in varied metabolic pathways, such as glycolysis, the tricarboxylic acid (TCA) cycle,
lipid metabolism, and deoxynucleotide biosynthesis, and catalyze different reactions. In most
cases, RNA binding was observed in vitro, using ﬁlter binding or electrophoretic mobility shift
assays [12,15,18–20]. While most of the reported moonlighting metabolic enzymes still await
validation in living cells and animals, the functions and modes of RNA binding of aconitase 1
(ACO1, also known as iron regulatory protein 1, IRP1), GAPDH, and TYMS have been explored
by biophysical and structural approaches [21], and investigated in cellular and animal models as
described later [22–25]. Insights from these examples form the basis of the ‘REM (RNA–
enzyme–metabolite) hypothesis’, which proposes the existence of regulatory links between
gene expression and intermediary metabolism mediated by moonlighting RNA-binding meta-
bolic enzymes [17].
Recent system-wide approaches have been developed to identify a (near) complete compen-
dium of RBPs. Initially, two parallel works used Saccharomyces cerevisiae proteome-wide
protein arrays to interrogate protein binding to RNA in vitro. These studies catalogued 180
[26] and 42 proteins [27], respectively, as putative RBPs, including many not previously known to
interact with RNA. Among the dozen metabolic enzymes reliably associated with RNA in vitro,
oxidoreductases and proteins involved in lipid metabolism were the most prominent classes of
putative moonlighting metabolic enzymes. The peroxisomal malate dehydrogenase (MDH3) was
identiﬁed in both studies as an RBP; immunoprecipitation followed by microarray (RIP-Chip)
showed modest RNA-binding capacity towards a limited pool of target RNAs [26]. Because the
peroxisome is not an organelle classically associated with RNA biology, these results called for
further experimental validation in cellular models.
To address the technical limitations of in vitro RBP identiﬁcation screens, two groups developed
in parallel a new approach named RNA interactome capture (Figure 1). Applying UV cross-
linking to proliferative cell monolayers, followed by stringent denaturing oligo(dT) isolation of
protein–RNA complexes and quantitative mass spectrometry, these studies identiﬁed a total of
1106 high-conﬁdence RBPs in HeLa and HEK293 cells [28,29]. Notably, hundreds of them were
novel RNA interactors and lacked known RNA-binding domains (RBDs). This method offers
several advantages over previous approaches: (i) UV light promotes free radical formation at the
nucleotide base that can establish covalent bonds only with amino acids placed at ‘zeroTrends in Endocrinology & Metabolism, December 2015, Vol. 26, No. 12 747
Glossary
Metabolon: an assembly of several
enzymes within a pathway with
superior metabolic ﬂux properties.
Moonlighting enzymes: enzymes
that carry out a function other than
their catalytic activity in metabolism;
here, we particularly focus on RNA-
binding enzymes.
REM (RNA–enzyme–metabolite)
hypothesis: a conceptual framework
suggesting that interactions among
RNA, enzymes, and metabolites
provide regulatory connections
between cellular metabolism and
gene regulation [17].
RNA interactome capture: an
experimental method to purify and
identify a near complete compendium
of proteins that interact with
polyadenylated RNAs in living cells.
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Figure 1. Schematic Representation of RNA Interactome Capture. Living cell monolayers are irradiated with UV
light to covalently link direct protein–RNA interactions. Polyadenylated RNA and covalently bound protein partners are
isolated by oligo(dT) pull-down under denaturing conditions. After RNase treatment, the RNA-binding protein (RBP)
repertoire is determined by quantitative mass spectrometry, comparing proteins isolated from crosslinked cells (cCL) with
those present in a mock pull-down (noCL). Only proteins with consistent enrichment across replicates (encircled in red) are
considered as the RNA interactome.distance’ (2 Å); (ii) UV crosslinking does not promote protein–protein crosslinks; (iii) because
UV is applied directly to living cells, hybridization with oligo(dT) captures native protein–RNA
complexes; (iv) nucleic acid hybridization is compatible with high salt and denaturing agents
including chaotropic detergents, thus allowing stringent removal of noncovalent binders; and (v)
to qualify as high-conﬁdence RBP, quantitative information and rigorous statistic methods are
applied [29,30].
Among the newly identiﬁed RBP classes, the RNA interactome studies reported 23 distinct
metabolic enzymes associated with polyadenylated RNAs [28,29,31] (Table 1), suggesting that
the interplay between RNA and metabolism is broader than previously realized and supporting
the REM network hypothesis. Among these moonlighters, aldolase and trifunctional enzyme
subunit b (HADHB) had previously been recognized to bind RNA in vitro [12] and the interaction
of enolase 1 (ENO1), hydroxymethyltransferase (SHMT1), and pyruvate kinase M2 (PKM2) with
RNA was validated in cells by an independent approach [29,30]. Applying UV crosslinking,
immunoprecipitation, and RNA sequencing (CLIPseq), it was shown that ENO1 and SHMT2
associate with hundreds of different mRNAs in HeLa cells, but display distinct binding patterns
from each other, suggesting selectivity of binding [29]. In agreement, bacterial enolase has been
recently identiﬁed, together with the RNase E, as a part of the degradosome complex, which
suggests that the relationship of this enzyme with RNA is already observable in prokaryotes [32].
Although the 23 moonlighting enzymes identiﬁed by the RNA interactome studies belong to
different metabolic pathways and catalyze distinct reactions, 13 of them bind either dinucleo-
tides or mononucleotides (Table 1). This suggests that protein domains commonly involved in
nucleotide binding, such as the Rossmann fold, may represent suitable protein surfaces to
interact with RNA, as discussed in more detail later.
Interestingly, some of the already known and newly discovered moonlighting RBPs are linked to
hereditary diseases. Mutations in inosine 50-monophosphate dehydrogenase 1 (IMPDH1), a dual
RNA-binding and dinucleotide-binding enzyme [33], cause retinitis pigmentosa [34], an eye
disease with severe vision impairment attributable to the progressive degeneration of the
photoreceptors in the retina [35]. Importantly, the disease-associated D226N IMPDH mutant
exhibits metabolic activity but it is unable to bind nucleic acids [36]. IMPDH is involved in the
post-transcriptional regulation of rhodopsin mRNA and this disease-associated mutation
reduces its association with polysomes and thus its translation efﬁciency [37]. Retinitis748 Trends in Endocrinology & Metabolism, December 2015, Vol. 26, No. 12
Table 1. Examples of Metabolic Enzymes Identiﬁed as RBPs in the RNA Interactome Studies
Gene Name Complete Name Function Di/mononucleotide
Binding
HeLa RNA
Interactome
HEK293 RNA
Interactome
mESC RNA
Interactome
ADK Adenylate kinase AMP biosynthesis ATP and adenosine Yes
ALDH18A1 Delta-1-pyrroline-5-carboxylate
synthase
Biosynthesis of proline, ornithine,
and arginine
ATP and NADP Yes
ALDH6A1 Methylmalonate-semialdehyde
dehydrogenase (acylating),
mitochondrial
Valine and pyrimidine metabolism NAD(P)/H Yes
ALDOA Fructose-bisphosphate aldolase A Glycolysis Yes
ASS1 Argininosuccinate synthase L-Arginine biosynthesis ATP Yes
CCBL2 Kynurenine–oxoglutarate
transaminase 3
Transaminase activity for several
amino acids
Yes
CS Citrate synthase, mitochondrial TCA cycle Yes
DUT Deoxyuridine 50-triphosphate
nucleotidohydrolase, mitochondrial
Nucleotide metabolism dUTP Yes Yes
ENO1 /-Enolase Glycolysis Yes Yes
FASN Fatty acid synthase Fatty acid synthesis NADP/H Yes Yes
FDPS Farnesyl pyrophosphate synthase Formation of farnesyl diphosphate Yes
GOT2 Aspartate aminotransferase,
mitochondrial
Amino acid metabolism Yes
HADHB Trifunctional enzyme subunit beta,
mitochondrial
beta-Oxidation of fatty acids Yes
HK2 Hexokinase-2 Glycolysis ATP Yes
HSD17B10 3-Hydroxyacyl-CoA dehydrogenase
type-2
b-Oxidation at position 17 of
androgens and estrogens
NAD/NAD(P) Yes
LTA4H Leukotriene A4 hydrolase Biosynthesis of leukotriene B4 Yes
MDH2 Malate dehydrogenase 2,
mitochondrial
TCA cycle NAD/H Yes Yes
NME1 Nucleoside diphosphate kinase A Synthesis of nucleoside
triphosphates
ATP Yes
NQO1 NAD(P)H dehydrogenase (quinone) 1 Detoxiﬁcation pathways and
vitamin K-dependent
g-carboxylation of glutamate
residues
NAD(P)H Yes
PKM2 Pyruvate kinase Glycolysis ATP Yes Yes
PPP1CC Serine/threonine–protein phosphatase
1–g catalytic subunit
Glycogen metabolism, muscle
contractility, and protein
synthesis
Yes
SUCLG1 Succinyl-CoA ligase
(ADP/GDP-forming) subunit
/, mitochondrial
TCA cycle ATP/GTP Yes
TPI1 Triosephosphate isomerase Glycolysis and gluconeogenesis Yes
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pigmentosa is also caused by mutations in components of the splicing machinery, such as
U4/U6 small nuclear ribonucleoprotein Prp3 (PRPF3), PRPF8, and PRPF31, suggesting a
considerable role of RNA biology in this disease [38].
The mitochondrial enzyme 17b-hydroxysteroid dehydrogenase 10 (HSD17B10; also known as
MRPP2), catalyzes the dehydrogenation of 17-hydroxysteroids in steroidogenesis. However, it
was catalogued as an RBP in HEK293 cells [28] and also moonlights as a component of
mitochondrial ribonuclease P, which is involved in the processing of the mitochondrial tRNAs
[39]. HSD17B10 deﬁciency causes neurodegeneration in humans and has been associated with
Alzheimer's disease. Curiously, there is no correlation between the degree of catalytic activity of
the disease-associated mutant enzymes and the severity of the disease [40], suggesting that the
molecular mechanism underlying this pathology does not primarily derive from the catalytic
activity of HSD17B10. Indeed, a recent study revealed that knock-down or mutation of
HSD17D10 induces a defect in the processing of the heavy strand of the mitochondrial
RNA [41]. In summary, abrogation of the RNA-related function of these moonlighting metabolic
enzymes is associated with phenotypic consequences, supporting the importance of these
protein–RNA interactions in cell biology.
The IRP1/Aconitase Paradigm
In the early 1990s, it became clear that the RBP intensively studied for its role in the regulation of
cellular iron metabolism, iron regulatory protein (IRP) 1, is identical with cytosolic aconitase [42–45].
The role of IRP1 in the post-transcriptional control of iron homeostasis illustrates the important
biological role that RNA-binding enzymes may play in vivo. RNA stem loop structures termed iron-
responsive elements (IREs) were ﬁrst found in the 50 untranslated regions (UTRs) of ferritin mRNAs
[46] and in the 30 UTR of transferrin receptor mRNA [47,48] (Figure 2). Speciﬁc IRE-binding proteins
were identiﬁed [49,50] and later termed iron regulatory protein 1 (IRP1) [51] and IRP2 [52,53]. IRE
motifs have since been found in other mRNAs, mostly encoding proteins involved in iron homeo-
stasis and utilization, and the mechanisms by which IRPs regulate these targets have been
elucidated [54]. Speciﬁcally, IRPs bind to RNAs in iron-deﬁcient cells, and interaction with an
IRE in the 50 UTR blocks mRNA translation, while binding to IREs in the 30 UTR leads to mRNA
stabilization; in this way, the IRPs are crucial to maintaining appropriate intracellular iron levels
(Figure 2A,B). Both proteins are broadly expressed across tissues and single knockout mice are
viable, while simultaneous knockout of both IRPs is early embryonic lethal, indicating essential but
largely redundant functions. Nevertheless, the single knockout phenotypes also demonstrate
speciﬁc roles for IRP1 in erythropoiesis and the cardiovascular system, while IRP2 is of particular
importance in erythroblasts and the nervous system (reviewed in [54–57]). Underscoring the
medical relevance of the IRP/IRE system, mutants of the IRE element of L-ferritin mRNA that lack
IRP binding cause hereditary hyperferritinemia–cataract syndrome [58].
IRP1 and IRP2 are 60% identical and both are homologous to the mitochondrial TCA
cycle enzyme aconitase ACO2 that catalyzes the isomerization of citrate to isocitrate using a
cubane iron sulfur cluster (4Fe–4S) as a cofactor. However, only IRP1 displays conservation of
the active site, assembles an equivalent 4Fe–4S cluster, and functions as a cytosolic aconitase.
RNA-binding and aconitase activity are mutually exclusive. In iron-replete conditions IRP1 ligates
the 4Fe–4S cluster and functions as an enzyme, while the cluster is disassembled when iron is
scarce and the IRP1 apoprotein binds IREs to its widened cleft [21] (Figure 2C,D). In most tissues
a large proportion of the IRP1 pool is in the enzymatically active holoenzyme state [59], leaving a
signiﬁcant reservoir for activation of RNA-binding activity in iron deﬁciency.
Moonlighting Central: GAPDH
A second well-characterized example of a protein with dual metabolic and RNA-binding
activity is the glycolytic enzyme GAPDH, which converts glyceraldehyde-3-phosphate to750 Trends in Endocrinology & Metabolism, December 2015, Vol. 26, No. 12
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Figure 2. Iron Regulatory Protein 1 (IRP1) Functions as Cytosolic Aconitase and RNA-Binding Protein (RBP).
(A) IRP1 binds to several mRNAs when not assembled with the 4Fe–4S cluster due to low intracellular concentrations of
iron. Among the best-studied examples is the binding of IRP1 to the iron-responsive element (IRE) in the 50 untranslated
region (UTR) of the ferritin mRNA to repress its translation. Since this mRNA encodes an iron-storage protein, diminished
ferritin levels will promote an increase of free iron. Conversely, IRP1 increases the stability of transferrin receptor mRNA when
binding to IREs in its 30 UTR. An increase in transferrin receptor levels will promote cellular iron uptake. (B) Conversely, when
IRP1 bears a 4Fe–4S cluster due to high intracellular iron concentration, it becomes active as cytosolic aconitase, catalyzing
the interconversion between citrate and isocitrate. (C) Ribbon diagram of IRP1 bound to an IRE (PDB 3SNP). (D) Ribbon
diagram of IRP1 crystalized as aconitase with the active site 4Fe–4S cluster (shown in red) (PDB 2B3Y).D-glycerate-1,3-bisphosphate, generating NADH. In addition to this ‘housekeeping’ role,
multiple functions in vesicular trafﬁcking, transcription, DNA repair, telomere maintenance,
and cell death have been reported, as reviewed in [60]. Of note, GAPDH is also a part of the
interferon g (IFNg)-activated inhibitor of translation (GAIT) complex that controls inﬂammatory
mRNA translation in myeloid cells [61]. The heterotetrameric GAIT complex contains the
glutamyl-prolyl tRNA synthase (EPRS), NS1-associated protein 1 (NSPA1, also known as
SYNCRIP or hnRNPQ), ribosomal protein L13a (L13a), and GAPDH. While NSPA1 is a
canonical RBP, EPRS, L13a, and GAPDH need to abandon their regular ‘tasks’ in the multi-
synthetase complex, the ribosome and glycolysis, respectively, to form the GAIT complex upon
phosphorylation of EPRS and L13a by IFNg-induced kinases [61]. EPRS is the main RNA-
binding speciﬁcity determinant within the GAIT complex; however, it is unknown whether
GAPDH also contributes to the interaction with target RNAs. GAPDH has also been identiﬁed as
an RBP in its own right, with reported targets ranging from mRNAs, tRNA, rRNA, a ribozyme,
and viral RNA (e.g., [20,62–64]). Multiple reports have focused on GAPDH binding to AU-rich
elements (AREs) in the 30UTR of numerous mRNAs [20,62,65–67]. Competition of RNA binding
with NAD+ and peptide mapping suggested that the dinucleotide-binding Rossmann fold
mediates binding to RNA [20].Trends in Endocrinology & Metabolism, December 2015, Vol. 26, No. 12 751
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Figure 3. Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) moonlights as an RNA-Binding Protein
(RBP) in Lymphocytes. (A) GAPDH binds the AU-rich element (ARE) present in the 30 untranslated region (UTR) of
interferon g (IFNg) mRNA in resting T cells relying on oxidative phosphorylation (OXPHOS), repressing IFNg expression. (B)
Engaged in glycolysis in activated T cells, GAPDH catalyzes the interconversion between glyceraldehyde-3-phosphate to D-
glycerate-1,3-bisphosphate using NAD+ as cofactor [25]. (C, D) Ribbon diagram of GAPDH bound to NAD either as a (C)
monomer or (D) tetramer (PDB 1ZNQ).An exciting ‘REM connection’ between gene regulation and metabolism involving GAPDH
emerged recently from the study of T cell activation [25] (Figure 3). When T lymphocytes are
activated, they switch from oxidative phosphorylation (OXPHOS) to aerobic glycolysis. In cells
relying on OXPHOS, translation of IFNg is repressed by binding of GAPDH to an ARE in the 30
UTR of the IFNg mRNA (Figure 3A). This repression is a direct effect of GAPDH as it was
preventable by RNAi knockdown, or forced engagement of the enzymatic function of GAPDH by
loading T cells with glyceraldehyde-3-phosphate. Following T cell activation and the switch to
aerobic glycolysis, GAPDH is no longer active as an RBP bound to IFNg mRNA and becomes
fully engaged in the glycolytic pathway (Figure 3B). Thus, the switch to aerobic glycolysis
emerges as a mechanism to antagonize the repression of effector cytokine production by
GAPDH, engaging the enzyme in glycolysis rather than RNA binding.
Competition between the enzyme cofactor NAD+ and RNA for binding to the same domain on
GAPDH could potentially be involved in the above-mentioned effects, as it has been demon-
strated that the presence of NAD+ or NADH interferes with RNA binding to GAPDH in vitro
[20,63,64,68,69]. By contrast, the substrate glyceraldehyde-3-phosphate has not shown
inhibition of RNA binding, consistent with the RNA interaction not being mediated by the
C-terminal substrate-binding region but through the N-terminal Rossmann fold. Enzyme activity
is abrogated by the addition of the IFNg 30 UTR in a sequence-dependent manner. The RNA also
inhibits the assembly of GAPDH monomers into the enzymatically active tetramer (Figure 3C),
suggesting that the enzyme binds RNA as a monomer or dimer [19].752 Trends in Endocrinology & Metabolism, December 2015, Vol. 26, No. 12
While NAD+ or NADH interference with RNA binding could be involved in switching between its
enzymatic and RNA regulatory functions, GAPDH is also known to be post-translationally
modiﬁed in various ways, with links to changes in its oligomerization state and subcellular
distribution, as reviewed in [60]. S-Nitrosylation by nitric oxide at the active site cysteine can
trigger GAPDH translocation to the nucleus and activation of its cell death-related functions, as
can ADP-ribosylation [70,71]. Intermolecular disulﬁde bond formation leads to formation of
cytoplasmic GAPDH amyloid-like ﬁbrils. Oxidative stress-induced S-glutathionylation of the
catalytically active cysteine allows the enzyme to participate in shifting metabolic ﬂux from
glycolysis to the pentose phosphate pathway [72,73]. Equally, a free sulfhydryl group has been
reported to be required for RNA binding [74], and S-glutathionylation to block the RNA-binding
activity of GAPDH [65]. Thus, alterations in cell state or metabolism could also affect the RNA-
binding/enzymatic function of GAPDH via post-translational modiﬁcations of the protein.
Who Affects Whom and How?
From a conceptual viewpoint, several distinct modes of RNA–enzyme interaction can be
envisaged (Figure 4, Key Figure): (i) RNA binding overlaps with the active site and/or cofac-
tor-binding pocket and is in direct competition with substrate or cofactors. If the afﬁnity of the
RNA to the enzyme is sufﬁciently high, this mode of interaction is expected to block catalysis by
the enzyme. (ii) The RNA binds to a distinct protein region away from the active site. Such an
interaction could either have no effect on catalysis or exert allosteric (positive or negative) effects
on the metabolic function of the enzyme. (iii) A special case of the latter scenario is that RNA
binding affects interactions of the enzyme with another cellular component, for example, a
membrane or other structural element (Figure 4A). (iv) Enzymes often function as homo- or
hetero-oligomeric complexes; hence, the interaction with RNA can further bridge between
complex subunits or interfere with assembly, when interacting with an oligomerization interface
of the enzyme (Figure 4B). And (v) larger assemblies can also exist where enzymes within a
pathway are held together by weak interactions to form a ‘metabolon’ with superior metabolicKey Figure
Is RNA Regulated by or the Regulator of Metabolic Enzymes? Several
distinct modes of RNA–enzyme interaction can be envisaged
(A) (B) (C)Monomer Oligomer Metabolon
∗
Substrate CofactorEnzymesKey: ∗ Post-translaonal modiﬁcaonRNACellular structure
Figure 4. (A) RNA binding overlaps with the active site and/or cofactor-binding pocket (top left) or is distant to it (top right).
RNA-binding activity could be regulated by metabolite-derived post-translational modiﬁcations (bottom left). RNA could
further regulate enzyme localization, for example, by attachment to a cellular structure such as a membrane (bottom right).
(B) RNA may also serve as scaffold for assembly of oligomers, or (C) multienzyme complexes into metabolons. See main text
for further discussion.
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Outstanding Questions
What is the physiological function of the
RNA-binding activity of so many meta-
bolic enzymes? Do these ‘moonlight’ in
the regulation of target (m)RNAs? Does
RNA affect aspects of their function as
metabolic enzymes?
Which RNAs bind to these enzymes?
Identiﬁcation of these by available tech-
nology should shed light on important
functional aspects
How do these enzymes bind RNA?
What are their RNA-binding domains
and do these overlap with regions that
are crucial for catalysis or complex
formation?
Are enzyme–RNA interactions regu-
lated? Do metabolic signals or metab-
olites affect these, and if so how is this
achieved?ﬂux properties [75–77]. RNA could conceivably bridge between enzymes of a pathway to foster
formation of a metabolon (Figure 4C). Interestingly, GAPDH appears to form a higher order
complex with other glycolytic enzymes, which was biochemically isolated and shown to be
sensitive to RNase digestion [78]. The metabolon concept was ﬁrst formulated for the TCA cycle
[76] and supported by recent work [79]. Similar evidence has been obtained for other pathways
such as the enzymes conducting de novo purine synthesis, which form purinosomes in the
cytoplasm [80]. There is much interest in engineering metabolons for superior performance in
biotechnology applications, and indeed a functional metabolon for hydrogen production in live
bacteria was designed based on an RNA scaffold [81]. Could RNA-augmented metabolons be a
more general occurrence in nature?
Although intuition inspired by existing examples such as aconitase/IRP1 and GAPDH might
suggest that an enzyme binding to RNA would control the expression of the RNA (e.g., IRP1
regulating ferritin mRNAs or GAPDH controlling IFNg mRNA translation), it is important to realize
that RNA may also affect the enzyme (e.g., its activity, localization, complex formation, biogene-
sis, stability, etc.). How would metabolism and metabolites affect this situation? First, metab-
olites and RNA could affect each other's interactions with the enzyme directly, either through
mutually exclusive binding to the same domain or through allosteric effects. Enzymes are often
allosterically regulated by metabolites other than their own substrates and thus a given enzyme–
RNA interaction might also be regulated by ‘out of left ﬁeld’ metabolites. Interestingly, even
canonical RBPs have been reported to be able to function as metabolite sensors, for example,
Musashi-1, which is allosterically inhibited by unsaturated fatty acids [82]. Second, cellular
metabolite levels might inﬂuence post-translational protein modiﬁcations [metabolite-driven
post-translational modiﬁcations (mPTMs)]. For example, many metabolic enzymes are acety-
lated and protein acetylation is linked to the cellular levels of both, acetyl-CoA and NAD+ [83].
Similar considerations apply to succinyl-CoA and succinylation, malonyl-CoA and malonylation,
S-adenosyl methionine and methylation, etc. Thus, metabolism could inﬂuence RNA binding to
enzymes indirectly, through changes in their PTM status; this could extend the regulatory scope
of a metabolite much beyond the enzyme that metabolizes it.
By contrast, RNA itself can act as an effector of the activity of an enzyme. The protein kinase R
(PKR) is activated by binding of (pathogen-derived) double-stranded RNA [84]. PKR in a
monomeric state is inactive; but the interaction with double-stranded RNA (viral replication
intermediaries) triggers its dimerization. As a dimer, PKR is active and can phosphorylate the
eukaryotic initiation factor 2/ (eIF2/), inducing the inhibition of host cell protein synthesis to
prevent viral replication and spread [85–87]. Other examples of RNA-regulated proteins include
RIG-I or Toll-like receptor (TLR) 3, TLR7, and TLR8 [88,89]. While these examples are taken from
the innate immune system and the regulatory RNAs are pathogen-derived, it is perfectly
conceivable that host cell genomes could express ‘effector RNAs’ to modulate the functions
of RNA-binding enzymes and other RBPs.
These possibilities still await experimental exploration for most of the moonlighting enzymes, as
even their physiological RNA partners are not yet known. Nevertheless, the above-mentioned
well-studied examples indicate that several, if not all, of the above scenarios deserve consid-
eration for their physiological relevance.
Concluding Remarks and Future Perspectives
Although cytosolic aconitase has been known for almost a quarter of a century to ‘moonlight’ as
an RBP that regulates cellular iron metabolism, it is only now becoming apparent that many
metabolic enzymes display RNA-binding activity in living cells. We can currently only speculate
about the physiological relevance of this widespread phenomenon, but we point to the urgency
of exploring this further to better understand whether and how metabolism and gene regulation754 Trends in Endocrinology & Metabolism, December 2015, Vol. 26, No. 12
might be coupled at this level (see Outstanding Questions). Speciﬁcally, we expect that the
identiﬁcation of the RNAs bound by/to different enzymes, and the exploration of their effect on
enzymatic function in different cellular contexts will be illuminating. It will also be important to
determine how changes in metabolism regulate the interactions between enzymes and RNA,
and what the biological consequences of this regulation are.
RNA-binding enzymes could open a whole new chapter in gene regulation and metabolism.
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